Abstract
Diabetic neuropathy (DN) is one of the diseases accountable for blindness in the developing countries. Presently, DN may be diagnosed with one among five patients suffering with diabetes. The assessment of DN is found to be difficult and challenging in clinical practice and clinical trials. Unfortunately, there is no single treatment exists to prevent or reverse neuropathic changes or to relieve pain. There are three major approaches for treatment of DN namely, intensive glycemic control, risk factor management and genetics configuration. Now, amitriptyline and duloxetine were identified for pain relief in DN. However, there is a growing need for research to evaluate most potent drugs and their combinations for management of DN so as to maximize pain relief and improve quality of life. A number of agents are potential candidates for use in DN therapy, Nav antagonists, N-type calcium channel blockers, NGF antibodies and angiotensin II type 2 receptor antagonists. In the present topic we discuss with modifying risk factors, genetics, and treatment of DN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
